AVTX - CIK 0001534120
The table below shows Avalo Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.99M | $26.96M | $42.29M | $125.05M | $81.86M | $93.43M |
| Short-term investments | $57.01M | $84.65M | $70.97M | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $88.83M |
| $113.85M |
| $115.19M |
| $126.94M |
| $86.15M |
| $95.89M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| Total assets | $99.89M | $125.10M | $126.58M | $138.52M | $98.45M | $108.31M |
| Accounts payable | $356.00K | $474.00K | $2.37M | $681.00K | $1.81M | $654.00K |
| Total current liabilities | $11.60M | $7.97M | $9.26M | $5.62M | $60.67M | $96.40M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $31.57M | $33.55M | $22.01M | $15.91M | $75.72M | $110.46M |
| Retained earnings | -$468.15M | -$434.80M | -$404.18M | -$383.41M | -$334.92M | -$357.96M |
| Total equity | $68.32M | $91.55M | $104.57M | $122.61M | $21.08M | -$13.61M |